Q4 EPS Estimate for Protagonist Therapeutics Cut by Analyst

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Stock analysts at HC Wainwright dropped their Q4 2025 EPS estimates for Protagonist Therapeutics in a note issued to investors on Monday, November 11th. HC Wainwright analyst D. Tsao now forecasts that the company will earn $0.87 per share for the quarter, down from their prior estimate of $0.88. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.33 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ FY2028 earnings at $2.81 EPS.

A number of other analysts have also commented on the company. JMP Securities reduced their target price on Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating for the company in a report on Wednesday, August 7th. BTIG Research upped their price objective on Protagonist Therapeutics from $41.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Wedbush reissued an “outperform” rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a research report on Monday, November 4th. JPMorgan Chase & Co. boosted their price target on Protagonist Therapeutics from $39.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, July 25th. Finally, StockNews.com upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $53.57.

Protagonist Therapeutics Stock Down 1.2 %

Protagonist Therapeutics stock opened at $42.67 on Wednesday. The company has a market capitalization of $2.54 billion, a P/E ratio of 16.00 and a beta of 2.17. Protagonist Therapeutics has a twelve month low of $15.58 and a twelve month high of $48.89. The stock’s 50 day moving average is $45.64 and its 200 day moving average is $38.46.

Insiders Place Their Bets

In other news, CFO Asif Ali sold 14,203 shares of the business’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total value of $631,891.47. Following the transaction, the chief financial officer now owns 34,960 shares of the company’s stock, valued at approximately $1,555,370.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director William D. Waddill sold 8,000 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total value of $360,000.00. Following the completion of the transaction, the director now owns 12,000 shares of the company’s stock, valued at approximately $540,000. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Asif Ali sold 14,203 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total value of $631,891.47. Following the sale, the chief financial officer now directly owns 34,960 shares in the company, valued at $1,555,370.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Protagonist Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Protagonist Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock worth $92,373,000 after buying an additional 39,055 shares during the period. Seven Eight Capital LP increased its stake in Protagonist Therapeutics by 426.9% in the second quarter. Seven Eight Capital LP now owns 36,793 shares of the company’s stock worth $1,275,000 after purchasing an additional 29,810 shares during the period. Bank of New York Mellon Corp increased its stake in Protagonist Therapeutics by 9.1% in the second quarter. Bank of New York Mellon Corp now owns 204,299 shares of the company’s stock worth $7,079,000 after purchasing an additional 17,065 shares during the period. New York State Teachers Retirement System bought a new stake in shares of Protagonist Therapeutics during the third quarter worth $1,107,000. Finally, Dark Forest Capital Management LP purchased a new stake in shares of Protagonist Therapeutics during the second quarter valued at $2,112,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.